3-异丙基-4-丁内酯 | 10547-88-3

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 中文名称: 3-异丙基-4-丁内酯
• 英文名称: (S)-4-Isopropyl-dihydro-furan-2-one
• 英文别名: 4-isopropyldihydrofuran-2(3H)-one；4-isopropyl-dihydro-furan-2-one；4-Isopropyl-dihydro-furan-2-on；(S)-β-(2-propyl)-γ-butyrolactone；(S)-4-Isopropyl-dihydrofuran-2-one；4-Isopropyldihydro-furan-2-one；4-propan-2-yloxolan-2-one
• CAS: 10547-88-3
• 化学式: C₇H₁₂O₂
• 分子量: 128.171
• InChiKey: KSHNENOHFJQWJE-UHFFFAOYSA-N

物化性质

• 沸点：
  60-62 °C(Press: 1 Torr)
• 密度：
  0.998±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  存在于白肋烟烟叶和香料烟烟叶中。

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

制备方法与用途

合成制备方法

• 烟草：BU、OR 和 18。

反应信息

• 作为反应物：
  描述：

  3-异丙基-4-丁内酯 在 碳酸氢钠 、 间氯过氧苯甲酸 、 lithium diisopropyl amide 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 3.0h， 生成 4-异丙基呋喃-2(5H)-酮
  参考文献：
  名称：

  Kametani, Tetsuji; Katoh, Tadashi; Tsubuki, Masayoshi, Chemical and pharmaceutical bulletin, 1985, vol. 33, # 1, p. 61 - 66

  摘要：

  DOI：
• 作为产物：
  描述：

  5-hydroxy-4-isopropylfuran-2(5H)-one 在 palladium on activated charcoal sodium tetrahydroborate 、 氢气 作用下， 以 甲醇 为溶剂， 反应 5.0h， 生成 3-异丙基-4-丁内酯
  参考文献：
  名称：

  Analogs of .gamma.-hydroxybutyric acid. Synthesis and binding studies

  摘要：

  Substituted 4-hydroxybutyric (GHB) or trans-4-hydroxycrotonic acids (T-HCA) and structurally related compounds were synthesized and submitted to [3H]GHB binding. Structure-activity relationships studies highlighted for [3H]GHB binding (a) the necessity of a nonlactonic, relatively extended conformation of the gamma-hydroxybutyric chain, (b) the existence of some bulk tolerance in the vicinity of the hydroxyl group, and (c) the high sensitivity toward isosteric replacements of the carboxyl or the hydroxyl groups. T-HCA has been recently identified as a naturally occurring substance in the central nervous system (CNS) and shows a better affinity than GHB. Our findings are in favor of the presence in the CNS of specific GHB binding sites, which are different from the GABA and the picrotoxin binding sites, and for which T-HCA may be an endogenous ligand.

  DOI：

  10.1021/jm00400a001

文献信息

• Pyrazole glucokinase activators
  申请人：Berthel Steven Joseph

  公开号：US20080021032A1

  公开（公告）日：2008-01-24

  Disclosed herein are pyrazole glucokinase activators of the formula (I) useful for the treatment of metabolic diseases and disorders, preferably diabetes mellitus.

  本文披露了一种式(I)的吡唑葡萄糖激酶激活剂，用于治疗代谢性疾病和紊乱，最好是糖尿病。
• Mono-and disubstituted 3-propyl gamma-aminobutyric acids
  申请人：——

  公开号：US20030181523A1

  公开（公告）日：2003-09-25

  The instant invention is a series of novel mono- and disubstituted 3-propyl gamma aminobutyric acids of Formula I 1 The compounds are useful as therapeutic agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, arthritis, sleep disorders, IBS, and gastric damage. Methods of preparing the compounds and useful intermediates are also part of the invention.

  这项即时发明是一系列新颖的单取代和双取代的Formula I的3-丙基γ-氨基丁酸。这些化合物在治疗癫痫、晕厥发作、运动减少、头颅疾病、神经退行性疾病、抑郁症、焦虑症、恐慌、疼痛、神经病理性疾病、关节炎、睡眠障碍、肠易激综合征和胃损伤方面是有用的治疗剂。制备这些化合物和有用中间体的方法也是该发明的一部分。
• Method of treating cartilage damage
  申请人：——

  公开号：US20020072533A1

  公开（公告）日：2002-06-13

  The invention relates to a method of preventing or treating cartilage damage by administering a GABA analog such as, for example, a compound of Formula 1 and pharmaceutically acceptable salts thereof, wherein R 1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

  该发明涉及通过给予类似GABA的类似物，例如Formula1的化合物及其药学上可接受的盐，来预防或治疗软骨损伤的方法，其中R1是氢或直链或支链低碳烷基，n为4至6的整数。
• Method of treating tinnitus
  申请人：——

  公开号：US20030176504A1

  公开（公告）日：2003-09-18

  The invention relates to a method of treating tinnitus by administering an alpha2delta ligand such as, for example, a compound of Formula 1 and pharmaceutically acceptable salts thereof, wherein R 1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

  这项发明涉及通过给予α2δ配体治疗耳鸣的方法，例如，给予一种符合化学式1的化合物及其药用盐，其中R1是氢或直链或支链低碳烷基，n为4至6的整数。
• Alpha2delta ligands for fibromyalgia and other disorders
  申请人：——

  公开号：US20040186177A1

  公开（公告）日：2004-09-23

  This invention relates to a method of treating a disorder selected from OCD, agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, PTSD, restless legs syndrome, premenstrual dysphoric disorder, hot flashes, and fibromyalgia by administering a compound of the formula 1 1 or a pharmaceutically acceptable salt thereof, wherein: R 1 is hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms or phenyl; and R 2 is straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The invention also relates to a method of treating the above disorders by administering the compound (3S, 5R)-3-Aminomethyl-5-methyl-octanoic acid

  这项发明涉及一种治疗选自强迫症、广场恐惧症、无惊恐障碍病史的广场恐惧症、特定恐惧症、社交恐惧症、创伤后应激障碍、不宁腿综合征、经前期抑郁症、潮热和纤维肌痛的方法，通过给予化合物11或其药学上可接受的盐，其中：R1是氢、1至6个碳原子的直链或支链烷基或苯基；和R2是4至8个碳原子的直链或支链烷基、2至8个碳原子的直链或支链烯基、3至7个碳原子的环烷基、1至6个碳原子的烷氧基、-烷基环烷基、-烷基烷氧基、-烷基羟基、-烷基苯基、-烷基苯氧基或-取代苯基。该发明还涉及通过给予化合物(3S, 5R)-3-氨甲基-5-甲基-辛酸来治疗上述疾病的方法。